Ultragenyx Pharmaceutical Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Good afternoon. My name is Gena Wang. I'm SMID Cap biotech analyst at Barclays. Welcome to our second virtual Global Healthcare Conference. First, I wish everyone stay healthy. And I would like to thank all the participants, investors, companies and especially our event team and corporate access team who made this virtual health care conference possible.
And with that, I would like to introduce, our next presenting company is Ultragenyx. With us today, we have Emil Kakkis, Chief Executive Officer. Also, we have Mardi Dier, Chief Financial Officer, with us. I will hand over to you, Emil, for a brief overview of the company.
Thanks, Gena, and happy to be here with you today. Ultragenyx has had a great 2020, even though it was a terrible 2020 overall for the world. But in our 10th year, we managed to now have 4 approvals, 2 of them last year and earned a moat of increasing revenue generation with $271
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |